Targets › NOROVIRUS
1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on NOROVIRUS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Anhui Zhifei Longcom Biologic Pharmacy | quadrivalent recombinant norovirus vaccine (Pichia pastoris) Recombinant norovirus VP1 capsid proteins (GI.1, GII.3, GII.4, GII.17) | NOROVIRUS | Phase 3 | Acute Gastroenteropathy Due to Norovirus | Mar 2027 |
Acute Gastroenteropathy Due to Norovirus (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.